Pharmacotherapy for neurogenic detrusor overactivity

Michael B. Chancellor, Rodney U. Anderson, Timothy B. Boone

Research output: Contribution to journalReview articlepeer-review

82 Scopus citations


Patients with neurogenic detrusor overactivity are a heterogeneous group with voiding dysfunction secondary to neurologic injury or disease. The neurogenic detrusor overactivity syndrome, which may include urinary frequency, urgency, and incontinence, frequently contributes to a loss of independence, or even institutionalization. Urodynamic assessment provides the best method of quantifying and classifying neurogenic detrusor overactivity dysfunction in patients with primary diagnoses as diverse as Parkinson's disease, cerebral palsy, multiple sclerosis, spinal cord injury, and spina bifida. For many patients, management of urinary symptoms includes pharmacotherapy with an anticholinergic agent. Several novel approaches to managing neurogenic detrusor overactivity, including intravesical instillation of anticholinergic agents, vanilloids, and neurotoxins, are being investigated. For most patients, however, flexible dosing with an anticholinergic agent, with clean intermittent catheterization when indicated, has been shown to reduce the risks of urologic complications, improve levels of continence, and enhance patient quality of life in both children and adults.

Original languageEnglish (US)
Pages (from-to)536-545
Number of pages10
JournalAmerican Journal of Physical Medicine and Rehabilitation
Issue number6
StatePublished - Jun 2006
Externally publishedYes


  • Anticholinergic
  • Neurogenic Detrusor Overactivity
  • Overactive Bladder
  • Pharmacotherapy

ASJC Scopus subject areas

  • Rehabilitation
  • Health Professions(all)
  • Orthopedics and Sports Medicine
  • Physical Therapy, Sports Therapy and Rehabilitation


Dive into the research topics of 'Pharmacotherapy for neurogenic detrusor overactivity'. Together they form a unique fingerprint.

Cite this